The American Journal of Managed Care

Type 2 Inflammation: A Common Theme Amongst Several Chronic Diseases

Reynold A. Panettieri Jr., MD, explores the impact of COPD and asthma on patients' quality of life, highlighting exercise limitations and sleep disturbances. Jonathan Silverberg, MD, PhD, MPH, ...
The American Journal of Managed Care

Type 2 Inflammation: The Link Between AD and PN

A dermatologist explores the underlying type 2 inflammatory pathway linking atopic dermatitis and prurigo nodularis, highlighting specific biomarkers that aid in identifying patients with type 2 ...
Fierce Biotech

Nektar eczema candidate 'checked all of the boxes' in long-term phase 2 data

Nektar Therapeutics is basking in the honeyed glow of long-term phase 2 data for its immune asset rezpegaldesleukin in atopic ...
BioSpace

Nektar’s Rezpeg Differentiates in Atopic Dermatitis With Durable, Deep Responses in Mid-Stage

The percentage of patients achieving total clearance of eczema lesions in a Phase 2b trial increased with prolonged rezpeg treatment.

Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis

INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical ...
MedPage Today

Dupilumab Improves Atopic Dermatitis, May Help Comorbidities in Very Young Children

In a post-hoc analysis, dupilumab improved symptoms of atopic dermatitis (AD) in young children ages 6 months to 5 years. Youngsters with associated comorbidities such as asthma, allergic rhinitis, ...